Main Menu


A phase II study of abiraterone in patients with recurrent ovarian, fallopian, or primary peritoneal cancer.

Disease site: Ovarian cancer

Treatment modality: Systemic therapy

Status: In follow up

Trial details

CORAL is a phase II, prospective, multicentre, open label, two stage trial to determine whether the drug abiraterone has clinical activity in patients with ovarian cancer that has relapsed within 12 months of treatment.

A total of 47 evaluable patients will be recruited from sites across the UK. Stage one of CORAL will recruit 26 patients, and if this is successful, stage two of the trial will recruit a further 21 patients. All participants will receive abiraterone 1000mg daily until progression and the number of patients taking part with androgren receptor positive disease will be carefully monitored.

If CORAL shows that abiraterone is a promising drug in this tumour group, the results could be used to design a follow on phase III multicentre randomised controlled trial.

Further information

Chief Investigator: Dr Susana Banerjee, The Royal Marsden NHS Foundation Trust

ICR-CTSU Scientific Lead: Professor Judith Bliss

Trial management contact: [email protected]

ISRCTN: 63407050

Co-sponsors: The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust

Funding: Janssen-Cilag Ltd and endorsed by Cancer Research UK’s Clinical Trials Awards & Advisory Committee (CRUKE/12/052)

View CORAL on the National Institute for Health Research website: NIHR - Be Part Of Research

A plain English summary of the CORAL trial is available from Cancer Research UK.

Publications and presentations

There have been no presentations or publications to date.

Clinical trials

Division of Clinical Studies

The division carries out or coordinates high-quality trials and translational research at both an early phase – typically to test new targeted drugs – and a later stage.